1. Research Compounds
2. Dosing & Kinetics Params
Dose Amount (Mg/Mcg Equivalent)
250 mg
Dosing Interval
Every 7 Days
Simulation Window
28 Days
Computed PK Metrics
Peak Conc. (Cmax)
18.40 ng/mL
Trough Conc. (Cmin)
9.20 ng/mL
Primary Pathway: Androgen Receptor (AR) Nuclear Translocation & VEGFR2 Angiogenesis
Evidence Tier Summary: Level 1 Human RCTs (Testosterone) / Level 3 Rodent Models (BPC-157)
Peptides / Receptors
Androgen Pathway
Downstream Gene Cascades
Pathway Crosstalk & Overlaps
Synergistic Receptor Activity Detected
Co-administration of Testosterone Enanthate and BPC-157 engages separate genomic (AR nuclear transcription) and non-genomic (VEGFR2 endothelial activation) repair cascades simultaneously.
Clinical Evidence Matrix
| Compound | Primary Target | Evidence Level |
|---|
* Level 1: Human RCTs | Level 2: Human Observational | Level 3: In-Vitro / Animal Models Only.